Preclinical evidence for cytokine-based immunotherapy in pancreatic cancer treatment: A systematic review.
Jorge Rodríguez-Criado, Alfonso J Corona-Castro, Francisco Quiñonero et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review assessed cytokine-based immunotherapy for pancreatic cancer, analyzing 46 preclinical studies. It found that targeting cytokines like TGF-β and IL-6 improved stromal remodeling, while pro-inflammatory cytokines enhanced T-cell persistence. The review highlights the potential of combining cytokine modulation with chemotherapy or checkpoint inhibitors to improve treatment outcomes.
Key findings
- Blocking TGF-β and IL-6 led to significant stromal remodeling and fibrosis reduction.
- Pro-inflammatory cytokines like IL-2, IL-12, and IL-15 enhanced T-cell persistence.
- Cytokine modulation alone was rarely sufficient but showed robust responses when combined with other therapies.
Why it matters
Understanding the role of cytokines in pancreatic cancer treatment could help clinicians develop more effective immunotherapy strategies, particularly in overcoming the challenges posed by the tumor microenvironment.
What to keep in mind
The review is limited by the use of subcutaneous and xenograft models that do not fully replicate human pancreatic stroma and varying risk of bias in studies.